

RANBAXY LIFE SCIENCES RESEARCH LIMITED

Head Office : 12th Floor, Devika Tower, Nehru Place, New Delhi-110 019

REPORT OF THE DIRECTORS

Your Directors have pleasure in presenting Fourth Annual Report of the Company and Audited Accounts for the year ended December 31, 2010.

Operations

The Company is not carrying any business activity. During the year under review, the Company has earned a interest income of Rs. 1,72,07,955 and profit after tax of Rs. 1,41,98,272, which has been transferred to the Reserves. The Board of Directors has not recommended any dividend.

Particulars with respect of Conservation of Energy/Technology Absorption and Foreign Exchange Earnings and Outgo

There are no particulars relevant to be furnished pertaining to conservation of energy/ technology absorption as required under the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988. Foreign exchange earnings and outgo was nil, during the year.

Fixed Deposits

The Company has not invited/received any fixed deposits during the year.

Particulars of Employees

As the Company did not pay any remuneration during the year, there are no particulars to be furnished under Section 217 (2A) of the Companies Act, 1956, and the Rules made thereunder.

Directors' Responsibility Statement

In terms of provisions of Section 217(2AA) of the Companies Act, 1956, (Act) your Directors confirm that :

- (i) In the preparation of the annual accounts, the applicable accounting standards have been followed alongwith proper explanation relating to material departures, wherever applicable;
- (ii) The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at the end of the accounting year and of the profit of the Company for that period;
- (iii) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (iv) The Directors have prepared the annual accounts on a going concern basis.

RANBAXY LIFE SCIENCES RESEARCH LIMITED

Head Office : 12th Floor, Devika Tower, Nehru Place, New Delhi-110 019

Directors

In accordance with Articles of Association of the Company, Mr. Sandeep Mehandroo, Director, retires by rotation at the ensuing Annual General Meeting and is eligible for re-appointment.

Auditors

M/s. B S R & Co., Chartered Accountants, retire as Auditors at the conclusion of the ensuing Annual General Meeting and have confirmed their eligibility and willingness to accept the office of Auditors, if re-appointed.

Audit Committee

The Company has an Audit Committee comprising of Mr. S. K. Patawari, Mr. Maninder Singh and Mr. Sandeep Mehandroo.

On behalf of the Board of Directors

Place: Gurgaon
Dated: March 22, 2011

Sd/-
(S. K. PATAWARI)
DIRECTOR

Sd/-
(SANDEEP MEHANDROO)
DIRECTOR

BSR & Co.

(Registered)

Chartered Accountants

Building No.10, 8th Floor, Tower-B
DLF Cyber City, Phase - II
Gurgaon - 122 002 (India)

Telephone:+91-124-2549191
Fax: +91-124-2549101

Auditors' Report

To the Members of
Ranbaxy Life Sciences Research Limited

- a) We have audited the attached Balance Sheet of Ranbaxy Life Sciences Research Limited ('the Company') as at 31 December 2010 and also the Profit and Loss Account and the Cash Flow Statement (collectively referred to as 'financial statements') of the Company for the year ended on that date, annexed thereto. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.
- b) We conducted our audit in accordance with auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statements presentation. We believe that our audit provides a reasonable basis for our opinion.
- c) As required by the Companies (Auditor's Report) Order, 2003 ('the Order'), issued by the Central Government of India in terms of sub-section (4A) of Section 227 of the Companies Act, 1956 ('the Act'), we enclose in the Annexure, a statement on the matters specified in paragraph 4 and 5 of the said Order.
- d) Further to our comments in the annexure referred to above, we report that:
 - i) we have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - ii) in our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - iii) the Balance Sheet, Profit and Loss Account and Cash Flow Statement dealt with by this report are in agreement with the books of account;
 - iv) in our opinion, the Balance Sheet, Profit and Loss Account and Cash Flow Statement dealt with by this report comply with the Accounting Standards referred to in sub-section (3C) of Section 211 of the Act to the extent applicable;

V Aggarwal

- v) on the basis of written representations received from the directors of the Company as at 31 December 2010, and taken on record by the Board of Directors, we report that none of the directors is disqualified as at 31 December 2010 from being appointed as a director in terms of clause (g) of sub-section (1) of Section 274 of the Act;
- vi) in our opinion, and to the best of our information and according to the explanations given to us, the said financial statements give the information required by the Act, in the manner so required and gives a true and fair view in conformity with the accounting principles generally accepted in India:
 - (i) in the case of the Balance Sheet, of the state of affairs of the Company as at 31 December 2010;
 - (ii) in the case of the Profit and Loss Account, of the profit for the year ended on that date; and
 - (iii) in the case of the Cash Flow Statement, of the cash flows for the year ended on that date.

For BSR & Co.
Chartered Accountants
Registration No.: 101248W



Vikram Aggarwal
Partner
Membership No.: 089826

Place: Gurgaon
Date: 22/02/2011

Annexure to the Auditors' Report

(Referred to in our report of even date)

- (i) The Company does not have any fixed assets. Accordingly, the provisions of clause 4(i) of the Order are not applicable.
- (ii) The Company does not have any inventory. Accordingly, the provisions of clause 4(ii) of the Order are not applicable.
- (iii) (a) The Company has neither granted nor taken any loans, secured or unsecured to or from companies, firms or other parties covered in the register maintained under Section 301 of the Act during the year, except for an interest-free, unsecured advance given to Ranbaxy Life Sciences Research Limited Employee Welfare Fund Trust, a party covered in the register maintained under Section 301 of the Act. The year-end balance and the maximum amount outstanding during the year in respect of this advance is Rs. 6,100,000 (previous year Rs. 6,100,000).
 - (b) As explained to us, the above advance was given for the purpose of subscribing to the shares of the Company itself, in accordance with the stock option scheme. This transaction was duly approved by the Board of Directors of the Company. Accordingly, the terms and conditions on which the above mentioned interest-free advance has been granted is prima facie, not prejudicial to the interest of the Company.
 - (c) No repayments of the above mentioned advance have fallen due during the current year.
 - (d) There is no overdue amount of more than Rupees one lakh in respect of the above mentioned advance.
- (iv) The activities of the Company do not involve purchase of inventories and sale of goods and services. There was no purchase of fixed assets during the year. Accordingly, the provisions of clause 4(iv) of the Order are not applicable.
- (v) In our opinion, and according to the information and explanations given to us, there are no contracts and arrangements the particulars of which need to be entered into the register maintained under section 301 of the Act.
- (vi) The Company has not accepted any deposits from the public.
- (vii) In our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- (viii) The Central Government has not prescribed the maintenance of cost records under Section 209(1)(d) of the Act for any of the activities carried out by the Company.
- (ix) (a) According to the information and explanations given to us, and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Income-tax have been regularly deposited during the year by the Company with the appropriate authorities. As explained to us, the Company did not have any dues on account of Provident fund, Employees' state insurance, Investor Education and Protection Fund, Sales-tax, Customs duty, Wealth tax, Excise duty and Service tax and other material statutory dues.

V. S. Srinivasan

There are no dues on account of Cess under Section 441A of the Act, since the date from which the aforesaid section comes into force has not yet been notified by the Central Government.

According to the information and explanations given to us, no undisputed amounts payable in respect of Income-tax were in arrears as at 31 December 2010 for a period of more than six months from the date they became payable.

- (b) In our opinion and according to the information and explanations given to us, there are no dues of Income-tax which have not been deposited with the appropriate authorities on account of any dispute.
- (x) The Company does not have accumulated losses at the end of the financial year and has not incurred cash losses during the financial year and in the immediately preceding financial year.
- (xi) The Company did not have any dues to financial institutions, bankers and debenture holders during the year.
- (xii) The Company has not granted any loans and advances on the basis of security by way of pledge of shares, debentures and other securities.
- (xiii) In our opinion and according to the information and explanations given to us, the Company is not a chit fund or a nidhi/ mutual benefit fund/ society.
- (xiv) According to the information and explanations given to us, the Company is not dealing or trading in shares, securities, debentures and other investments.
- (xv) In our opinion and according to the information and explanations given to us, the Company has not given any guarantee for loans taken by others from banks or financial institutions.
- (xvi) In our opinion and according to the information and explanations given to us, the Company did not have any term loans outstanding during the year.
- (xvii) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we are of the opinion that the funds raised on short-term basis have not been used for long-term investment.
- (xviii) The Company has not made any preferential allotment of shares during the year to parties and companies covered in the register maintained under Section 301 of the Act.
- (xix) The Company has not issued any debentures during the year.
- (xx) The Company has not raised any money by public issues during the year.

V. Aggarwal

BSR & Co.

(xxi) According to the information and explanations given to us, no fraud on or by the Company has been noticed or reported during the course of our audit.

Place: Gurgaon
Date: 22/02/2011

For BSR & Co.
Chartered Accountants
Registration No.: 101248W



Vikram Aggarwal
Partner
Membership No.: 089826

Ranbaxy Life Sciences Research Limited
Balance Sheet as at 31 December 2010
(Amount in Rupees)

	Schedule/Note	As at 31 December 2010	As at 31 December 2009
SOURCES OF FUNDS			
Shareholders' funds			
Share capital	1	50,600,000	50,600,000
Reserve and surplus	2	217,172,365	202,974,093
Loan funds			
Unsecured loans	3	2,000,000	-
Total		269,772,365	253,574,093
APPLICATION OF FUNDS			
Investments	4	-	237,464,215
Current assets, loans and advances			
Cash and bank balances	5	259,389,795	778,567
Loans and advances	6	6,549,150	6,100,000
Other current assets	7	3,870,783	11,209,423
		269,809,728	18,087,990
Less: Current liabilities and provisions			
Current liabilities	8	37,363	34,164
Provisions	9	-	1,943,948
		37,363	1,978,112
Net current assets		269,772,365	16,109,878
Total		269,772,365	253,574,093
Significant accounting policies	10		
Notes to the financial statements	11		

The schedules referred to above form an integral part of the Balance Sheet

As per our report attached

For **B S R & Co.**
Chartered Accountants
Registration No.: 101248W

For and on behalf of the Board of Directors

Sd/-
Vikram Aggarwal
Partner
Membership No.: 089826

Sd/-
Maninder Singh
Director

Sd/-
Sandeep Mehandroo
Director

Sd/-
Akhilesh Nand
Company Secretary

Place: Gurgaon
Date: 22 February 2011

Place: Gurgaon
Date: 22 February 2011

Ranbaxy Life Sciences Research Limited
Profit and Loss Account for the year ended 31 December 2010
(Amount in Rupees)

	Schedule/Note	For the year ended 31 December 2010	For the year ended 31 December 2009
INCOME			
Interest on deposits with banks (gross of tax deducted at source Rs. 776,756 (previous year Rs. 2,422,879))		7,775,231	11,959,985
Interest from investments		9,432,724	6,891,758
		<u>17,207,955</u>	<u>18,851,743</u>
EXPENDITURE			
Loss on sale of non trade current investment		157,768	-
Legal and professional		25,122	15,024
Auditors' remuneration (including service tax)			
- Statutory audit fees		20,681	20,681
- Tax audit		6,894	-
- Out of pocket expenses		2,317	-
Rates and taxes		2,000	-
Miscellaneous expenses		11,244	1,038
		<u>226,026</u>	<u>36,743</u>
Profit before tax		16,981,929	18,815,000
Provision for tax - current tax	11(9)	2,800,000	5,700,000
Tax - earlier years		(16,343)	-
Profit after tax		14,198,272	13,115,000
Balance brought forward from previous year		22,974,093	9,859,093
Balance carried forward to Schedule 2		37,172,365	22,974,093
Earnings per equity share			
Basic and diluted (refer to note 2 of schedule 11)		0.46	0.43

Significant accounting policies 10

Notes to the financial statements 11

The schedules referred to above form an integral part of the Profit and Loss Account

As per our report attached

For **B S R & Co.**
Chartered Accountants
Registration No.: 101248W

For and on behalf of the Board of Directors

Sd/-
Vikram Aggarwal
Partner
Membership No.: 089826

Sd/-
Maninder Singh
Director

Sd/-
Sandeep Mehandroo
Director

Sd/-
Akhilesh Nand
Company Secretary

Place: Gurgaon
Date: 22 February 2011

Place: Gurgaon
Date: 22 February 2011

Ranbaxy Life Sciences Research Limited
Cash Flow Statement for the year ended 31 December 2010
(Amount in Rupees)

	For the year ended 31 December 2010	For the year ended 31 December 2009
A. Cash flow from operating activities		
Net profit before tax	16,981,929	18,815,000
Adjustments for :		
Loss on sale of non trade current investment	157,768	-
Interest on deposits with banks	(7,775,231)	(11,959,985)
Interest from investment	(9,432,724)	(6,891,758)
Operating loss before working capital changes	(68,258)	(36,743)
Adjustments for :		
Increase in current liabilities	3,199	20,681
Cash used in operations	(65,059)	(16,062)
Direct taxes paid	(5,176,755)	(3,698,879)
Net cash used in operating activities	(5,241,814)	(3,714,941)
B. Cash flow from investing activities		
Interest received	24,546,595	9,328,769
Investments in bonds	(150,260,250)	(237,464,215)
Proceeds from sale of investments	387,566,697	-
Decrease/(increase) in fixed deposit with original maturity of more than 90 days	(258,300,000)	231,800,000
Net cash generated from investing activities	3,553,042	3,664,554
C. Cash flow from financing activities		
Proceeds from short term loan	6,500,000	-
Payment of short term loan	(4,500,000)	-
Net cash flow from financing activities	2,000,000	-
Net increase / (decrease) in cash and cash equivalents	311,228	(50,387)
Cash and cash equivalents at the beginning of the year	78,567	128,954
Cash and cash equivalents at the end of the year	389,795	78,567
Add:		
Fixed deposit with original maturity of more than 90 days	259,000,000	700,000
Cash and bank balance at the end of the year	259,389,795	778,567

Note :

The above cash flow statement has been prepared under the indirect method set out in Accounting Standard 3 'Cash Flow Statement' specified in the Companies (Accounting Standards) Rules, 2006.

As per our report attached

For **B S R & Co.**
Chartered Accountants
Registration No.: 101248W

For and on behalf of the Board of Directors

Sd/-
Vikram Aggarwal
Partner
Membership No.: 089826

Sd/-
Maninder Singh
Director

Sd/-
Sandeep Mehandroo
Director

Sd/-
Akhilesh Nand
Company Secretary

Place: Gurgaon
Date: 22 February 2011

Place: Gurgaon
Date: 22 February 2011

Ranbaxy Life Sciences Research Limited
Schedule forming part of the financial statements
For the year ended 31 December 2010
(Amount in Rupees)

	As at 31 December 2010	As at 31 December 2009
SCHEDULE - 1		
Share capital		
Authorised		
150,000,000 (previous year 150,000,000) equity shares of Re. 1 each	150,000,000	150,000,000
2,000,000 (previous year 2,000,000) redeemable preference shares of Rs. 100 each	200,000,000	200,000,000
	350,000,000	350,000,000
Issued, subscribed and paid up		
Equity shares		
30,600,000 (previous year 30,600,000) of Re. 1 each (out of the above, 24,500,000 (previous year 24,500,000) shares are held by Ranbaxy Laboratories Limited, the holding Company along with its nominees Daiichi Sankyo Co., Ltd., Japan is the ultimate holding Company) (refer to note 4 of Schedule 11)	30,600,000	30,600,000
Preference shares		
2,000,000 (previous year 2,000,000) redeemable Preference shares of Rs. 100 each, paid up amount Rs. 10 per share (refer to note 6 of Schedule 11) (above preference shares are held by Ranbaxy Laboratories Limited, the holding Company) (refer to note 6 of Schedule 11)	20,000,000	20,000,000
	50,600,000	50,600,000
SCHEDULE - 2		
Reserves and surplus		
Share premium account	180,000,000	180,000,000
Profit and Loss Account	37,172,365	22,974,093
	217,172,365	202,974,093
SCHEDULE - 3		
Unsecured loan		
Interest free loan from holding company	2,000,000	-
	2,000,000	-
SCHEDULE - 4		
Investments		
Current		
Unquoted, non-trade		
Investments in tax free bonds		
- 6.85% India Infrastructure Finance Company Limited (IIFCL) bonds (Nil, previous year 100,000 units)	-	100,650,000
- 0% National Bank for Agricultural and Rural Development (NABARD) bonds (Nil, previous year 14,545 units) (refer to note 7 of Schedule 11)	-	136,814,215
	-	237,464,215
SCHEDULE - 5		
Cash and bank balances		
Balances with scheduled banks		
- in current account	389,795	78,567
- in deposit account	259,000,000	700,000
	259,389,795	778,567

Ranbaxy Life Sciences Research Limited
Schedule forming part of the financial statements
For the year ended 31 December 2010
(Amount in Rupees)

	As at 31 December 2010	As at 31 December 2009
SCHEDULE - 6		
Loans and advances		
(Unsecured, considered good)		
Advance to Ranbaxy Life Sciences Research Limited Employees' Welfare Fund Trust (refer to note 4 of schedule 11)	6,100,000	6,100,000
Advance tax and tax deducted at source (net of provision for tax Rs. 6,300,000)	449,150	-
	<u>6,549,150</u>	<u>6,100,000</u>
SCHEDULE - 7		
Other current assets		
Interest accrued on 6.85% IIFCL bonds	-	6,455,890
Interest accrued on 0% NABARD bonds	-	4,752,306
Interest accrued but not due on deposits	3,870,783	1,227
	<u>3,870,783</u>	<u>11,209,423</u>
SCHEDULE - 8		
Current liabilities		
Sundry creditors (refer to note 8 of schedule 11)	35,295	21,755
Other liabilities	2,068	12,409
	<u>37,363</u>	<u>34,164</u>
SCHEDULE - 9		
Provisions		
Provision for tax (previous year net of advance tax Rs. 9,736,052)	-	1,943,948
	<u>-</u>	<u>1,943,948</u>

SCHEDULE – 10

Significant accounting policies

Basis of accounting

The financial statements have been prepared and presented under the historical cost convention on the accrual basis of accounting and comply with the Accounting Standards as specified in the Companies (Accounting Standards) Rules, 2006, other pronouncements of the institutes of Chartered Accountants of India, and the relevant provisions of the Companies Act, 1956, to the extent applicable.

Use of estimates

The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses for the year. Actual results could differ from these estimates. Any revision to accounting estimates is recognized prospectively in the current and future periods.

Revenue Recognition

Interest income is recognized using time proportion method.

Investments

Investments that are readily realizable and intended to be held for not more than a year are classified as current investments. All other investments are classified as long-term investments.

Current investments are carried at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost less any other-than-temporary diminution in value, determined, separately in respect of each category of investment.

Taxes on incomes

Income tax expense comprises current tax (i.e. amount of tax for the year determined in accordance with the Income tax –law) and deferred tax charge or credit

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using tax rates that can be enacted or substantively enacted by the balance sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognised only if there is virtual certainty of realisation of such assets. Deferred tax assets are reviewed at each balance sheet date and are written –down or written –up to reflect the amount that is reasonably /virtually certain (as the case may be) to be realised.

Minimum alternate tax payable under the provisions of the Income Tax Act, 1961 is recognized as an asset in the year in which credit becomes eligible and is set off to the extent allowed in the year in which the Company becomes liable to pay income taxes at the enacted tax rates.

SCHEDULE – 10(Cont'd)

Provisions, contingent liabilities and contingent assets

A provision is created when there is a present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

The Company does not recognise assets which are of contingent nature until there is virtual certainty of realisability of such assets. However, if it has become virtually certain that an inflow of economic benefits will arise, assets and related income is recognised in the financial statements of the period in which the change occurs.

Earnings per share

Basic earning per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average numbers of equity shares outstanding during the period are adjusted for events of bonus issue and share split. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares. The dilutive potential equity shares are deemed converted as of the beginning of the period, unless they have been issued at a later date.

SCHEDULE – 11

Notes to the financial statements

1. Background

The Company was incorporated on 27 December 2006 and was granted certificate of commencement of business on March 26, 2007. The Company has been set up to carry on the business of Research & Development in the field of drug discovery, biosciences, new drugs delivery system, pharmaceutical products and its intermediate.

2. Earnings per share

Particulars	For the year ended 31 December 2010	For the year ended 31 December 2009
Weighted average number of shares	30,600,000	30,600,000
Net profit after tax attributable to equity shareholders.	14,198,272	13,115,000
Basic and diluted earnings per share	0.46	0.43
Nominal value per equity share	1	1

3. Segment information

In the opinion of the management, there is only one segment as envisaged by Accounting Standard 17 “Segment Reporting”. Accordingly, no disclosure for segment reporting has been made in the financial statements.

4. During the year 2008, the Company gave an advance of Rs. 6,100,000 to Ranbaxy Life Sciences Research Limited Employee Welfare Fund Trust (‘the trust’) to subscribe for its own shares pursuant to a Scheme of Stock Options Plan approved by the Board of Directors of the Company on 19 February 2008. In accordance with the scheme, the trust shall manage the allotment of the stock option to the eligible employees to be determined from time to time. Accordingly, the paid up equity share capital includes the shares held by the trust amounting to Rs. 6,100,000 and the same also appears as advance to the trust. However, as there are no employees on the payroll of the Company, no shares have yet been allotted.

SCHEDULE -11 (Cont'd)

5. Related party Disclosures

a) The following transactions were carried out with related parties:

Related party	Nature of transactions	Description of relationship	Year ended 31 December 2010	Year ended 31 December 2009
Daiichi Sankyo Co., Ltd., Japan	-	Ultimate holding company	-	-
Ranbaxy Laboratories Limited	Loan taken	Holding company	65,00,000	-
Ranbaxy Laboratories Limited	Loan repaid	Holding company	45,00,000	

b) Balances outstanding

Related party	Nature of transactions	Description of relationship	As at 31 December 2010	As at 31 December 2009
Ranbaxy Life Sciences Research Limited employee welfare trust	Advance	Enterprise under the common control of the holding company	6,100,000	6,100,000
Ranbaxy Laboratories Limited	Loan taken	Holding company	20,00,000	-

6. In one of the earlier years, the Company issued Zero percent redeemable preference share of face value of Rs. 100 per share to Ranbaxy Laboratories Limited (RLL), the holding Company at a price of Rs. 1,000 per share (including premium of Rs. 900 per share). The called up amount on these preference shares is Rs. 100 per share (including Rs. 90 per share towards share premium account). As per the terms of the agreement (modified in the previous year), these preference shares are redeemable at par.

7. Details of investment purchased and sold during the year ended 31 December 2010 are as follows:

Particulars	Purchase and sold units*	Purchase value (Rs.)	Sale Value (Rs.)
6.85% IIFCL -2014	365,000	37,540,250	37,339,500
9.00% IRFC -2019	1000,000	112,720,000	111,852,300

SCHEDULE -11 (Cont'd)

8. The Ministry of Micro, Small and Medium Enterprises has issued an Office Memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum. Based on the information available with the management, there are no overdues outstanding to micro and small enterprises as defined under the Micro, Small and Medium Enterprises Development Act, 2006. Further, the Company has not received any claim for interest from any supplier under the said Act.
9. Provision for tax includes credit of Rs. 1,615,309 (previous year Rs. Nil) relating to earlier year.

For and on behalf of the Board of Directors

Sd/-
Maninder Singh
Director

Sd/-
Sandeep Mehandroo
Director

Sd/-
Akhilesh Nand
Company Secretary

Place: Gurgaon
Date: 22 February 2011

RANBAXY LIFE SCIENCES RESEARCH LIMITED

BALANCE SHEET ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE

I. Registration Details

Registration No.
 State Code
 Balance Sheet Date
 Date
 Month
 Year

II. Capital Raised during the year (Amount in Rs. Thousands)

Public Issue
 Right Issue
 Bonus Issue
 Private Placement

III. Position of Mobilisation and Deployment of funds (Amount in Rs. Thousands)

Total Liabilities
 Total Assets
 Source of Funds
 Paid-up Capital
 Reserves & Surplus
 Secured Loans
 Unsecured Loans
 Application of Funds
 Net Fixed Assets
 Investments
 Net Current Assets
 Miscellaneous Expenditure
 Accumulated Losses

IV. Performance of Company (Amount in Rs. Thousands)

Turnover
 Total Expenditure
 Profit Before Tax
 Profit After Tax
 Earning Per Share in Rs.
 Dividend Rate %

V. Generic Names of Three Principal Products/Services of the Company (as per Monetary terms)

Item Code No. (ITC Code)
 Product Description

For and on behalf of the Board of Directors

Sd/- Maninder Singh
 Director
 Sd/- Sandeep Mehandroo
 Director

Sd/- Akhilesh Nand
 Company Secretary

Place: Gurgaon
 Date: 22 February 2011